On Wednesday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Travelport Worldwide (NYSE:TVPT), Celldex Therapeutics, (NASDAQ:CLDX), Calpine (NYSE:CPN), Alaska Air Group, (NYSE:ALK)

Formerly On March 20, 2015 Travelport Worldwide Ltd (NYSE:TVPT) a leading Travel Commerce Platform providing distribution, technology, payment and other solutions for the $7 trillion global travel and tourism industry, uncovered June 11, 2015 as the date for the Company’s 2015 Annual General Meeting of Shareholders (the “Annual Meeting”). The exact time and location will be specified in the Company’s proxy statement related to the Annual Meeting. The Board of Directors has established April 17, 2015 as the record date for determining investors entitled to vote at the Annual Meeting.

Travelport Worldwide Ltd (NYSE:TVPT)’s shares picked down -3.41%, and closed at $16.13. The stock volatility for the week is 3.70%, while for the month remained 3.31%. The company holds consensus target price of $18.20.

If we consider EPS growth of the company, then the company indicated the following observations:

The company showed 1.14 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained 156.00% and Annual EPS growth for the past 5 years is considered as 1.50%.

The mean recommendation of analysts for this stock is 1.80. (Where 1=Buy, 5=Sale).

Travelport Worldwide Ltd (TVPT) provides travel commerce platform that offers distribution, technology, payment, and other solutions for the travel and tourism industry in the United States, the United Kingdom, and internationally.

Formerly On March 17, 2015 Celldex Therapeutics, Inc. (NASDAQ:CLDX) disclosed that it has entered into a clinical trial collaboration with Roche to evaluate the safety, tolerability and preliminary efficacy of varlilumab, Celldex’s CD27 targeting investigational antibody, and MPDL3280A (anti-PDL1), Roche’s investigational cancer immunotherapy in a Phase 1/2 study in renal cell carcinoma.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) declined -3.37%, and closed at $26.93. The company has the market capitalization of $2.73 billion. The beta value of the stock is 2.74. On the other hand the stock’s volatility for the week is 5.93%, and for the month is 6.36%. The stock’s price to book ratio is $11.41, however price to sale ratio is $732.57. Analyst’s mean recommendation regarding this stock is 1.30. (Where 1=Buy, 5=Sale).

Celldex Therapeutics, Inc. (CLDX) a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. The company’s lead drug candidates comprise rindopepimut (CDX-110), a targeted immunotherapeutic in a pivotal Phase III study for the treatment of front-line glioblastoma, as well as in Phase II study for the treatment of recurrent glioblastoma; and Glembatumumab vedotin (CDX-011), a targeted antibody-drug conjugate in a randomized Phase IIb study for the treatment of triple negative breast cancer, as well as in Phase II study for the treatment of metastatic melanoma.

Calpine Corporation (NYSE:CPN) proclaimed that it plans to release first quarter 2015 financial results on Friday, May 1, 2015, before the opening of the New York Stock Exchange. Management will present the results during an investor call scheduled for 10 a.m. Eastern Time / 9 a.m. Central Time on May 1.

Calpine Corporation (NYSE:CPN) decreased -3.37%, and closed at $22.10. The company holds the market capitalization of $8.60 billion. For the last twelve months, the stock was able to keep return on equity at 27.80%, while return on assets at 5.40%, in response to its return on investment at 11.10%. Its 20-day moving average gained 3.15%, below 50-day moving average of 2.81%, above 200-day moving average of -0.57% from the latest market price of $-0.57. The mean recommendation of analysts for this stock is 1.90. (Where 1=Buy, 5=Sale).

Calpine Corporation (CPN) a wholesale power generation company, owns and operates natural gas-fired and geothermal power plants in North America. It operates natural gas-fired combustion turbines and renewable geothermal conventional steam turbines.

Alaska Air Group, Inc. (NYSE:ALK) presented its application to start two nonstop services from Orange County, California, to Los Cabos and Puerto Vallarta, Mexico. The flights are pending approval by the U.S. Department of Transportation and the Mexico Direccion General de Aeronautica Civil (DGAC).

Alaska Air Group, Inc. (NYSE:ALK) fell -3.29%, and closed at $64.00. The stock has the beta value of 0.92, and its volatility for the week is 2.32%, while for the month it is 2.23%. The company has the market capitalization of $8.66 billion. The company holds the book value per share of 16.07, whereas cash per share is 9.28. Price to book ratio remained 3.98, while price to sale ratio is 1.56. Analysts mean recommendation for the stock is said to be 2.30 (where 1=Buy, 5=sale).

Alaska Air Group, Inc. (ALK) along with its subsidiaries, provides passengers and cargo air transportation services primarily in the United States. The company operates through Alaska Mainline and Alaska Regional segments.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.